ViroPharma Incorporated ~ Nasdaq Bio~ VPHM due diligence
VPHM Company Overview & Description
Quote:
Your Dream is our Vision: Life-saving medicines for life-threatening diseases
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI).
VPHM goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx the prescribing information for other countries can be found at http://www.viropharma.com.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
ViroPharma Europe is ViroPharma's wholly-owned European subsidiary, which commenced in 2007 to leverage in Europe the company's expertise in the development and commercialization of biotechnology products, and in business development. ViroPharma seeks to acquire opportunities in areas of strategic interest to the company; Our strategy is to target serious diseases by building franchises within narrowly focused prescribing groups, with an initial niche focus on C1 esterase inhibitor deficiency and seizures in children and adolescents. Our interest could expand into other areas if they are compatible with our general business plan (i.e. niche opportunities, supportable by specialty marketing).
- Belgium
- France
- Germany
- Italy
- Spain
- Switzerland
- United Kingdom
Colin Broom
Vice President, Chief Scientific Officer
Colin Broom, M.D. has served as Vice President, Chief Scientific Officer of ViroPharma since May 2004. From 2000 until 2003 Dr. Broom served as vice president of clinical development and medical affairs, Europe, for Amgen. From 1998 to 1999, Dr. Broom served as senior vice president of global clinical development for Hoechst Marion Roussel, now Aventis. From 1984 through 1998, Dr. Broom was with Glaxo and then SmithKline Beecham, where he held positions of increasing seniority in clinical pharmacology in Europe before moving to the US to head global oncology and subsequently becoming Vice President of CNS/GI. Dr. Broom holds a Bachelor of Science degree in pharmacology from University College in London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School. Dr. Broom is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.
Thomas F. Doyle
Vice President, Strategic Initiatives
Thomas F. Doyle is ViroPharma’s Vice President, Strategic Initiatives as of January 2008; he previously served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College.
Robert C. Fletcher
Vice President, Business Development and Project Management
Robert C. Fletcher is our Vice President, Business Development and Project Management. Mr. Fletcher joined ViroPharma in 2001 as a project leader, and has since held roles of increasing seniority during his tenure in the areas of business development and project management. Prior to joining ViroPharma, Mr. Fletcher held multiple roles of escalating responsibility at SmithKline Beecham Pharmaceuticals/GlaxoSmithKline, Becton-Dickinson and Company, Zynaxis Inc./Intracell Corporation, and Centocor Corporation. He holds both a master of science degree and a bachelor of arts degree in biology from Wake Forest University.
Vincent J. Milano
President, Chief Executive Officer and Chairman of the Board of Directors
Vincent Milano is ViroPharma’s President and Chief Executive Officer, and Chairman of the Board of Directors as of March 2008. He joined the company in 1996 and served as vice president, chief financial officer, and treasurer from 1997 to 2006. In 2006, he assumed the role of vice president, chief financial officer and chief operating officer. Mr. Milano has been instrumental in building ViroPharma, including leading efforts in raising nearly $900 million in capital and the acquisition of Vancocin(R) from Eli Lilly and Company. He has played a critical role in all business development and investor relations activities of the company, and has contributed significantly to establishing the strategic direction of the company. Prior to joining ViroPharma, he was with KPMG LLP, independent certified public accountants, where he served as senior manager. Mr. Milano received his bachelor of science degree in accounting from Rider College.
ViroPharma Incorporated
730 Stockton Drive
Exton, PA 19341
Voice: 610-458-7300
Toll-free Voice: 1-888-651-0201
Facsimile: 610-458-7380
For assistance in acquiring Cinryze™ (C1 Esterase Inhibitor [human]), please call the CINRYZESolutions Support Program at 1-877-945-1000
Website: http://www.viropharma.com
European Headquarters
ViroPharma SPRL - BVBA
rue Montoyer 47
1000 Brussels
Belgium
Tel: +32 (0)2 747 0971
Fax: +32 (0)2 706 2421
http://finance.yahoo.com/q/h?s=VPHM+Headlines
ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs.
Our product CINRYZE® (C1 Esterase Inhibitor [Human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a rare and potentially life threatening genetic inflammatory disorder. Our product VANCOCIN® is the only antibiotic approved to treat two significant bacterial infections of the lower digestive tract. The product is administered orally and is indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile
The company is also assessing non-toxigenic C. difficile (VP20621) with the goals of preventing the recurrence of disease following effective therapy for acute C. difficile infection (CDI) and preventing CDI in patients who are susceptible to colonization with toxigenic strains due to prior use of antibiotics.
VPHM follows under these quidelines on the Nasdaq market tier.
Investigate more @ http://www.otcmarkets.com/stock/VPHM/quote for more due diligence.
Share Structure
Market Cap a/o 1/2/11 1.93B
Number of shares outstanding of the issuer’s Common Stock, par value $.002 per share, as of October 18, 2011: 70,542,868 shares.
Common stock, par value $0.002 per share. 175,000,000 shares authorized; issued and outstanding 70,542,125 shares at September 30, 2011 and 78,141,491 shares at December 31, 2010
(per last 10Q, link posted below)
Float listed per Yahoo Fiance: 65.46M
Shareholders
Shareholders of Record: 213
Transfer Agent(s)
Broadridge Financial Solutions, Inc.
44 W. Lancaster Avenue
Ardmore, PA, 19003
610-649-7300
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
CIK: 0000946840
Fiscal Year End: 12/31
OTC Market Tier: M - Nasdaq
Profile Data
SIC - Industry Classification: # 2834
Business Status Development Stage Company: Health Care / Biotechnology
Incorporated In: DE, USA
Year of Inc: 1994
Employees: 232
Security Notes
New Issue=11-96 2,250,000 shs at $7 by Cowen & Co. et al.
OTC Disclosure last 10Q reported Oct 27, 2011 period ending Sept 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8207500
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, VPHM website
Images by StocksDiva
StocksDiva has not been compensated for these images in this post
Due Diligence by PYCK Global Marketing
PYCK Global Marketing has not been compensated for this Due Diligence post
No comments:
Post a Comment